|Bid||231.91 x 1000|
|Ask||232.33 x 1300|
|Day's range||227.62 - 233.76|
|52-week range||117.58 - 242.97|
|Beta (5Y monthly)||0.50|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||246.39|
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., February 02, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2022 on Thursday, February 23, 2023, before the U.S. financial markets open.
Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.